Inozyme Pharma

Investment area
Novo Ventures
Region
Eastern USA
Date of investment
January 2017

Inozyme Pharmaceuticals develops enzyme replacement therapies to treat orphan diseases characterized by aberrant calcification as a result of inorganic pyrophosphate (PPi) deficiency.

Inozyme Pharma

Investment area
Novo Ventures
Region
Eastern USA
Date of investment
January 2017

Inozyme Pharmaceuticals develops enzyme replacement therapies to treat orphan diseases characterized by aberrant calcification as a result of inorganic pyrophosphate (PPi) deficiency.

Inozyme Pharma

Investment area
Novo Ventures
Region
Eastern USA
Date of investment
January 2017

Inozyme Pharmaceuticals develops enzyme replacement therapies to treat orphan diseases characterized by aberrant calcification as a result of inorganic pyrophosphate (PPi) deficiency.